Objectives. The aims were to evaluate the prevalence of anti-drug antibodies (ADA) in patients with RA or SpA experiencing secondary failure to anti-TNF therapy and to correlate ADA presence with anti-TNF concentration and clinical response.
Introduction
The treatment of RA, AS and PsA has been greatly improved by the introduction of anti-TNF agents [13] . However, a proportion of patients receiving these biologic therapies persist with active disease, either because the treatment fails to initiate a response (primary failure) or because initial responsiveness gives rise to non-response (secondary failure). Secondary failure can occur in as many as 30% of patients [4] . A potential reason for secondary failure is the development of anti-drug antibodies (ADA), which can neutralize the drug or decrease the serum drug concentrations to sub-therapeutic levels, resulting in a loss of clinical response [57] . There are reports showing loss of efficacy owing to development of ADA against infliximab (INF) and adalimumab (ADL) [8] . Furthermore, ADA may also cause acute or delayed reactions, such as infusion-and injection-site reactions [9] .
The purpose of this observational study was to evaluate the prevalence of ADA against anti-TNF agents in Spanish patients with RA or SpA with secondary failure, and to assess whether the presence of ADA and low serum drug concentrations were the reasons for the lack of clinical response.
Methods

Patients and study design
The REASON study was a cross-sectional, observational investigation carried out in 45 rheumatology centres across Spain between November 2012 and July 2014. Patients were eligible for inclusion if they were aged 518 years, had active RA or SpA, including PsA, and had received and complied with anti-TNF [etanercept (ETN), INF or ADL] treatment as prescribed by a rheumatologist. Patients with secondary failure to anti-TNF treatment at the time of the study visit were included consecutively. Secondary failure was defined as good response (DAS28 <3.2, AS DAS 4 2.1 or BASDAI < 4) in response to the administered anti-TNF treatment for at least 3 months and moderate-to-high disease activity (DAS28 53.2 or AS DAS >2.1 or BASDAI 54) at the time of evaluation in the present study. Patients with low disease activity (RA: DAS28 < 3.2; SpA: AS DAS < 2.1 or BASDAI 4 4) were excluded. Treatment with concomitant non-biologic DMARDs during the study was permitted.
All patients provided signed and dated informed consent, and the study was approved by the ethics committee of La Paz University Hospital in Madrid. This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki, and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines.
Assessments
Serum drug and ADA concentrations were measured with two-site ELISA using Promonitor (Proteomika) kits [10] . All assays were performed in a central reference laboratory. The limit of detection for serum INF, ADL and ETN was 2, 0.4 and 1.2 mg/ml, respectively, and for the corresponding ADA was 1, 1.7 and 6.9 a.u./ml (100% specificity), respectively.
Statistical analysis
It was assumed that a sample size of 552 patients diagnosed with RA or SpA on anti-TNF treatment and with secondary failure to treatment would allow the estimation of the prevalence of anti-TNF antibodies with 95% CI, a power of 80%, and a precision of 0.0425 and 0.044, respectively. A prevalence of patients with RA or SpA who develop anti-TNF antibodies of 32 and 28%, respectively, and a reposition rate of 10% were assumed. Demographic and clinical characteristics were summarized using descriptive statistics. Quantitative and qualitative variables were analysed using measurements of central tendency (mean, median) and of dispersion (95% CI). Qualitative variables were defined according to their absolute and relative frequencies. Pearson's 2 test was used for qualitative variables. Data were analysed using SPSS V17.0 statistical software.
Results
Patient population
A total of 583 patients were recruited, and 570 were considered evaluable (RA: n = 276; SpA: n = 294, of whom 103 were diagnosed with PsA). At baseline, the demographics and characteristics of patients with RA were significantly different from those with SpA (Table 1) . The majority of patients with RA were female (80%), whereas the majority of patients with SpA were male (61% Fig. 1B] . A statistical analysis could not be performed for patients treated with ETN because no patient developed ADA (Fig. 1B) .
Correlation between ADA, serum drug concentrations and RA markers Overall, 92/114 (80.7%) patients who tested positive for ADA had no detectable drug in the serum (Fig. 1C) 
Discussion
In this observational study of patients with RA or SpA and secondary failure treated with anti-TNF agents, we found that 20% of the study population tested positive for ADA. All these patients were treated with either ADL or INF; no patient treated with ETN tested positive for ADA. Overall, the rates of ADA formation were similar among patients treated with ADL and patients treated with INF. Of the 114 patients who developed ADA, 81% had no detectable drug concentrations in their serum. The development of ADA, therefore, appears to be a major contributor to reduced serum drug concentrations and, consequently, secondary treatment failure in this population. Other factors contributing to secondary failure potentially include compliance, obesity and monotherapy with biologics; however, these were beyond the scope of the present study and, consequently, not evaluated.
The absence of anti-ETN antibodies in our study is corroborated by other studies of the immunogenicity of ETN [4, 11, 12] . Similar studies in patients with RA have reported the presence of anti-ADL antibodies in 754% of patients [4, 13, 14] and anti-INF antibodies in 1047% of patients [13, 15] . The wide variability of detection methods, thresholds, patient demographics, disease severity and the use of concomitant DMARDs in these studies could have contributed to the range in the rates of ADA reported.
Nevertheless, the prevalence of ADA reported in our study, by far the largest, is consistent with previous reports.
In our study, patients with SpA appeared significantly more likely to develop anti-INF antibodies than those with RA. The reason for this is unclear. Our analysis showed that more than half the patients with SpA testing positive for ADA received INF monotherapy, whereas patients with RA all received concomitant DMARDs. This interpretation is supported by the fact that in the overall population, a significantly lower proportion of patients receiving concomitant DMARDs developed ADA compared with those receiving biologic monotherapy.
When ADA are present, serum drug concentrations are usually undetectable. Secondary loss of efficacy attributable to low serum concentrations is not uncommon with TNF inhibitors. In the ATTRACT trial on patients with RA, 2030% of patients receiving 3 mg/kg INF every 8 weeks had undetectable pre-infusion trough serum concentrations from week 22 to 54 of treatment; the majority of these patients also demonstrated poor clinical response [16] . In RA patients, low pre-infusion serum INF concentrations may herald the formation of anti-INF antibodies and are associated with a higher risk of treatment failure [15] . Development of ADA often results in the formation of drugantibody complexes, which may be eliminated much faster than unbound drug, thereby changing the pharmacokinetic profile of the drug, resulting in potential loss of efficacy [17] .
In our study, we identified a proportion of patients with ADA and detectable low concentrations of drug. Similar results were reported by Chen et al. [18] in a different population. Although this is not usual with bridging ELISA, drug interference has been reported in some assays [19] . There were also several patients in the ADLand INF-treated groups who had low or no drug concentrations and no detectable ADA. Although poor compliance to therapy could be an explanation when it comes https://academic.oup.com/rheumatology to patients receiving ADL, which is self-administered, it cannot be a cause of low drug concentrations for INFtreated patients, because this drug is administered in a hospital. Another possible reason is that those patients had ADA, but the real frequency of immunogenicity is underestimated when using bridging ELISA because free serum drug concentrations and drugantibody complexes cannot always be detected by this method [20] . This cross-sectional observational study design provided some insights into medical practice in Spain but also uncovered some limitations. Sample collection from patients at a single time point without follow-up prevented any longitudinal analysis of clinical responses or the impact of historical treatments. It is also possible that there might be variations among health professionals in the routine use of the different clinical screening scales and treatment decisions. It is assumed that higher doses of biologics might have been administered by some physicians to counteract loss of efficacy. However, pharmacokinetic modelling suggests that decreasing the dose interval would raise low trough serum concentrations more effectively than increasing the dose [16] .
ELISAs are subject to false-positive and false-negative results caused by non-specific binding or epitope masking [20] . Thus, owing to interference in the bridging ELISA, it is possible that patients identified as having low concentrations of drug in their serum might have no drug present. Furthermore, the kit used to measure ETN could not discriminate between drug concentrations, so analyses were limited to the presence or absence of ETN.
In conclusion, we identified ADA in almost 30% of the population of patients treated with ADL or INF for rheumatic disease. No ADA were detected against etanercept. Although the presence of ADA was clearly a contributing factor of secondary failure to therapy in most cases, immunogenicity could not explain all cases of failure. Further investigations could help to determine all possible causes of failure of anti-TNF therapy.
